Hematologic Malignancies – Expert Insights from Charles Craddock
Professor Craddock discusses three hematology-oncology abstracts from the ASCO21 Annual Meeting reporting on the use of letermovir to prevent cytomegalovirus reactions in allogeneic stem cell transplant recipients with graft versus host disease (abstract 7004), first-line asparcytarabine in acute myeloid leukemia patients unfit for standard chemotherapy, and the initial results from the V-FAST trial of CPX-351 plus targeted agents for newly diagnosed acute myeloid leukemia.
Interviewee: Charles Craddock, CBE, FRCP, FRCPath, DPhil
Affiliation(s): Queen Elizabeth Hospital, University of Birmingham, UK
Disclaimer: Springer Healthcare selected the experts for interview. The expert interviews appearing herein were not prepared or reviewed by ASCO and have not been subject to a peer review process. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. Read full disclaimer here.
Expert insights into key ASCO21 data that will impact clinical practice and patient
care plus complimentary access to 50 official ASCO video presentations and
downloadable slides, picked by our Experts.
ASCO Direct is an officially licensed program of the American Society of Clinical Oncology® (ASCO®)
This program is supported by Bristol Myers Squibb and brought to you by Springer Healthcare